Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.

More From Author

Leaving Has Its Costs — See Also

NYT Connections today — hints and answers for Friday, July 19 (game #404)

Leave a Reply

Your email address will not be published. Required fields are marked *